Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Merck & Co. describes new adenosine A2A and/or A2B receptor antagonists

June 10, 2020

Grey Wolf Therapeutics synthesizes ERAP1 inhibitors

June 10, 2020

Phase I study finds manageable toxicity with LY-2880070 alone and with gemcitabine

June 10, 2020

First patient dosed in phase Ib study of RMC-4630 in combination with AMG-510

June 10, 2020

BeyondSpring presents positive data from PROTECTIVE-2 study of plinabulin plus Neulasta

June 10, 2020

Beijing Scitech-Mq Pharmaceuticals patents new compounds for cancer

June 9, 2020

Shanghai De Novo Pharmatech identifies ATR kinase inhibitors

June 9, 2020

Nanjing Sanhome Pharmaceutical synthesizes new TGFR-1 inhibitors

June 9, 2020

Inflazome patents NLRP3 inhibitors

June 9, 2020

FDA accepts IND application for TAS-0953/HM-06

June 9, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....